UCB Likely to Focus on Early-Stage Assets for Next Deals
Dow Jones09-24 22:33
1432 GMT - UCB's portfolio offers growth potential into the next decade after the acquisitions of Candid Therapeutics and Neurona, so the Belgian drugmaker's next deals might target early-stage assets, Bank of America analysts say. Data due next year from a midstage trial of its galvokimig eczema drug candidate will likely inform UCB's decision on whether it needs to add further late-stage medicines to its pipeline over time, the analysts say. UCB executives seemed confident at a Bank of America event that the company's top-selling product Bimzelx can withstand competition from new drugs, the analysts say in a research note. Shares rise 0.6%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments